azacitidine and venetoclax for MDS and AML – pro
Venetoclax plus decitabine or azacitidine showed tolerable safety and favorable overall response rate (CR + CRi rate: 67%) in elderly patients with AML. This combination regimen produced favorable responses in high-risk groups, such as age 75 or older, poor cytogenetics, and secondary AML. It is listed by NCCN.
Courtney D. DiNardo , Keith Pratz , Vinod Pullarkat , Brian A. Jonas , Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva , Andrew H. Wei, Hagop M. Kantarjian, Tu Xu , Wan-Jen Hong, Brenda Chyla, Jalaja Potluri , Daniel A. Pollyea, Anthony Leta, iVenetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood (2019) 133 (1): 7–17.
Jilg, S., Hauch, R.T., Kauschinger, J. et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. Exp Hematol Oncol 8, 9 (2019). https://doi.org/10.1186/s40164-019-0133-1
NCCN AML 2021